EVALUATION OF THE USE OF DISEASE-MODIFYING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BRAZIL

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, characterized by inflammation, demyelination, and potential neurodegenerative damage. Among its subtypes, Relapsing-Remitting Multiple Sclerosis (RRMS) is the most common, marked by episodic relapses followed by periods of remission. This exploratory study utilized DATASUS data to analyze the pharmacological treatment profile of RRMS in Brazil between 2020 and 2023. Findings indicate that the Southeast region had the highest number of treated patients, followed by the South and Northeast, with the North showing lower incidence rates, suggesting a need for further epidemiological studies. A decline in the use of beta-interferons and glatiramer acetate was noted, contrasting with a significant increase in natalizumab utilization. These insights are crucial for understanding treatment practices and regional health policies for RRMS in Brazil.